Search

Your search keyword '"Kerber, Romy"' showing total 34 results
Start Over Author "Kerber, Romy"
34 results on '"Kerber, Romy"'

1. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack

Author

Bonilla, Weldy V., Kirchhammer, Nicole, Marx, Anna-Friederike, Kallert, Sandra M., Krzyzaniak, Magdalena A., Lu, Min, Darbre, Stéphanie, Schmidt, Sarah, Raguz, Josipa, Berka, Ursula, Vincenti, Ilena, Pauzuolis, Mindaugas, Kerber, Romy, Hoepner, Sabine, Günther, Stephan, Magnus, Carsten, Merkler, Doron, Orlinger, Klaus K., Zippelius, Alfred, and Pinschewer, Daniel D.

Published
2021
Full Text
View/download PDF

3. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

Author

Sissoko, Daouda, Duraffour, Sophie, Kerber, Romy, Kolie, Jacques Seraphin, Beavogui, Abdoul Habib, Camara, Alseny-Modet, Colin, Géraldine, Rieger, Toni, Oestereich, Lisa, Pályi, Bernadett, Wurr, Stephanie, Guedj, Jeremie, Nguyen, Thi Huyen Tram, Eggo, Rosalind M, Watson, Conall H, Edmunds, W John, Bore, Joseph Akoi, Koundouno, Fara Raymond, Cabeza-Cabrerizo, Mar, Carter, Lisa L, Kafetzopoulou, Liana Eleni, Kuisma, Eeva, Michel, Janine, Patrono, Livia Victoria, Rickett, Natasha Y, Singethan, Katrin, Rudolf, Martin, Lander, Angelika, Pallasch, Elisa, Bockholt, Sabrina, Rodríguez, Estefanía, Di Caro, Antonino, Wölfel, Roman, Gabriel, Martin, Gurry, Céline, Formenty, Pierre, Keïta, Sakoba, Malvy, Denis, Carroll, Miles W, Anglaret, Xavier, and Günther, Stephan

Published
2017
Full Text
View/download PDF

6. Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015

Author

Kerber, Romy, Krumkamp, Ralf, Diallo, Boubacar, Jaeger, Anna, Rudolf, Martin, Lanini, Simone, Bore, Joseph Akoi, Koundouno, Fara Raymond, Becker-Ziaja, Beate, Fleischmann, Erna, Stoecker, Kilian, Meschi, Silvia, Mély, Stéphane, Newman, Edmund N. C., Carletti, Fabrizio, Portmann, Jasmine, Korva, Misa, Wolff, Svenja, Molkenthin, Peter, Kis, Zoltan, Kelterbaum, Anne, Bocquin, Anne, Strecker, Thomas, Fizet, Alexandra, Castilletti, Concetta, Schudt, Gordian, Ottowell, Lisa, Kurth, Andreas, Atkinson, Barry, Badusche, Marlis, Cannas, Angela, Pallasch, Elisa, Bosworth, Andrew, Yue, Constanze, Pályi, Bernadett, Ellerbrok, Heinz, Kohl, Claudia, Oestereich, Lisa, Logue, Christopher H., Lüdtke, Anja, Richter, Martin, Ngabo, Didier, Borremans, Benny, Becker, Dirk, Gryseels, Sophie, Abdellati, Saïd, Vermoesen, Tine, Kuisma, Eeva, Kraus, Annette, Liedigk, Britta, Maes, Piet, Thom, Ruth, Duraffour, Sophie, Diederich, Sandra, Hinzmann, Julia, Afrough, Babak, Repits, Johanna, Mertens, Marc, Vitoriano, Inês, Bah, Amadou, Sachse, Andreas, Boettcher, Jan Peter, Wurr, Stephanie, Bockholt, Sabrina, Nitsche, Andreas, Županc, Tatjana Avšič, Strasser, Marc, Ippolito, Giuseppe, Becker, Stephan, Raoul, Herve, Carroll, Miles W., De Clerck, Hilde, Van Herp, Michel, Sprecher, Armand, Koivogui, Lamine, Magassouba, N'Faly, Keïta, Sakoba, Drury, Patrick, Gurry, Cèline, Formenty, Pierre, May, Jürgen, Gabriel, Martin, Wölfel, Roman, Günther, Stephan, and Di Caro, Antonino

Published
2016

8. Unique human immune signature of Ebola virus disease in Guinea

Author

Ruibal, Paula, Oestereich, Lisa, Ldtke, Anja, Becker-Ziaja, Beate, Wozniak, David M., Kerber, Romy, Korva, Mia, Cabeza-Cabrerizo, Mar, Bore, Joseph A., Koundouno, Fara Raymond, Duraffour, Sophie, Weller, Romy, Thorenz, Anja, Cimini, Eleonora, Viola, Domenico, Agrati, Chiara, Repits, Johanna, Afrough, Babak, Cowley, Lauren A., Ngabo, Didier, Hinzmann, Julia, Mertens, Marc, Vitoriano, Ins, Logue, Christopher H., Boettcher, Jan Peter, Pallasch, Elisa, Sachse, Andreas, Bah, Amadou, Nitzsche, Katja, Kuisma, Eeva, Michel, Janine, Holm, Tobias, Zekeng, Elsa-Gayle, Garca-Dorival, Isabel, Wlfel, Roman, Stoecker, Kilian, Fleischmann, Erna, Strecker, Thomas, Di Caro, Antonino, Avi-upanc, Tatjana, Kurth, Andreas, Meschi, Silvia, Mly, Stephane, Newman, Edmund, Bocquin, Anne, Kis, Zoltan, Kelterbaum, Anne, Molkenthin, Peter, Carletti, Fabrizio, Portmann, Jasmine, Wolff, Svenja, Castilletti, Concetta, Schudt, Gordian, Fizet, Alexandra, Ottowell, Lisa J., Herker, Eva, Jacobs, Thomas, Kretschmer, Birte, Severi, Ettore, Ouedraogo, Nobila, Lago, Mar, Negredo, Anabel, Franco, Leticia, Anda, Pedro, Schmiedel, Stefan, Kreuels, Benno, Wichmann, Dominic, Addo, Marylyn M., Lohse, Ansgar W., De Clerck, Hilde, Nanclares, Carolina, Jonckheere, Sylvie, Van Herp, Michel, Sprecher, Armand, Xiaojiang, Gao, Carrington, Mary, Miranda, Osvaldo, Castro, Carlos M., Gabriel, Martin, Drury, Patrick, Formenty, Pierre, Diallo, Boubacar, Koivogui, Lamine, Magassouba, NFaly, Carroll, Miles W., Gnther, Stephan, and Muoz-Fontela, Csar

Subjects
Ebola hemorrhagic fever -- Physiological aspects, Medical research, Immune response -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): Paula Ruibal [1, 2, 3, 4]; Lisa Oestereich [2, 3, 4]; Anja Ldtke [1, 2, 3, 4]; Beate Becker-Ziaja [2, 3, 4]; David M. Wozniak [2, 3, 4]; Romy [...]

Published
2016
Full Text
View/download PDF

11. Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa

Author

Carroll, Miles W., Matthews, David A., Hiscox, Julian A., Elmore, Michael J., Pollakis, Georgios, Rambaut, Andrew, Hewson, Roger, García-Dorival, Isabel, Bore, Joseph Akoi, Koundouno, Raymond, Abdellati, Saïd, Afrough, Babak, Aiyepada, John, Akhilomen, Patience, Asogun, Danny, Atkinson, Barry, Badusche, Marlis, Bah, Amadou, Bate, Simon, Baumann, Jan, Becker, Dirk, Becker-Ziaja, Beate, Bocquin, Anne, Borremans, Benny, Bosworth, Andrew, Boettcher, Jan Peter, Cannas, Angela, Carletti, Fabrizio, Castilletti, Concetta, Clark, Simon, Colavita, Francesca, Diederich, Sandra, Donatus, Adomeh, Duraffour, Sophie, Ehichioya, Deborah, Ellerbrok, Heinz, Fernandez-Garcia, Maria Dolores, Fizet, Alexandra, Fleischmann, Erna, Gryseels, Sophie, Hermelink, Antje, Hinzmann, Julia, Hopf-Guevara, Ute, Ighodalo, Yemisi, Jameson, Lisa, Kelterbaum, Anne, Kis, Zoltan, Kloth, Stefan, Kohl, Claudia, Korva, Miša, Kraus, Annette, Kuisma, Eeva, Kurth, Andreas, Liedigk, Britta, Logue, Christopher H., Lüdtke, Anja, Maes, Piet, McCowen, James, Mély, Stéphane, Mertens, Marc, Meschi, Silvia, Meyer, Benjamin, Michel, Janine, Molkenthin, Peter, Muñoz-Fontela, César, Muth, Doreen, Newman, Edmund N. C., Ngabo, Didier, Oestereich, Lisa, Okosun, Jennifer, Olokor, Thomas, Omiunu, Racheal, Omomoh, Emmanuel, Pallasch, Elisa, Pályi, Bernadett, Portmann, Jasmine, Pottage, Thomas, Pratt, Catherine, Priesnitz, Simone, Quartu, Serena, Rappe, Julie, Repits, Johanna, Richter, Martin, Rudolf, Martin, Sachse, Andreas, Schmidt, Kristina Maria, Schudt, Gordian, Strecker, Thomas, Thom, Ruth, Thomas, Stephen, Tobin, Ekaete, Tolley, Howard, Trautner, Jochen, Vermoesen, Tine, Vitoriano, Inês, Wagner, Matthias, Wolff, Svenja, Yue, Constanze, Capobianchi, Maria Rosaria, Kretschmer, Birte, Hall, Yper, Kenny, John G., Rickett, Natasha Y., Dudas, Gytis, Coltart, Cordelia E. M., Kerber, Romy, Steer, Damien, Wright, Callum, Senyah, Francis, Keita, Sakoba, Drury, Patrick, Diallo, Boubacar, de Clerck, Hilde, Van Herp, Michel, Sprecher, Armand, Traore, Alexis, Diakite, Mandiou, Konde, Mandy Kader, Koivogui, Lamine, Magassouba, N’Faly, Avšič-Županc, Tatjana, Nitsche, Andreas, Strasser, Marc, Ippolito, Giuseppe, Becker, Stephan, Stoecker, Kilian, Gabriel, Martin, Raoul, Hervé, Di Caro, Antonino, Wölfel, Roman, Formenty, Pierre, and Günther, Stephan

Published
2015
Full Text
View/download PDF

12. A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2′O-Methylated Self RNA

Author

Schuberth-Wagner, Christine, Ludwig, Janos, Bruder, Ann Kristin, Herzner, Anna-Maria, Zillinger, Thomas, Goldeck, Marion, Schmidt, Tobias, Schmid-Burgk, Jonathan L., Kerber, Romy, Wolter, Steven, Stümpel, Jan-Philip, Roth, Andreas, Bartok, Eva, Drosten, Christian, Coch, Christoph, Hornung, Veit, Barchet, Winfried, Kümmerer, Beate M., Hartmann, Gunther, and Schlee, Martin

Published
2015
Full Text
View/download PDF

13. Additional file 1 of Variation around the dominant viral genome sequence contributes to viral load and outcome in patients with Ebola virus disease

Author

Xiaofeng Dong, Munoz-Basagoiti, Jordana, Rickett, Natasha Y., Pollakis, Georgios, Paxton, William A., Günther, Stephan, Kerber, Romy, Ng, Lisa F. P., Elmore, Michael J., N’faly Magassouba, Carroll, Miles W., Matthews, David A., and Hiscox, Julian A.

Abstract

Additional file 1: Supplementary figures S1-S7 and tables S1-S4.

Published
2020
Full Text
View/download PDF

15. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Author

Sissoko, Daouda, Laouenan, Cedric, Folkesson, Elin, M'Lebing, Abdoul-Bing, Beavogui, Abdoul-Habib, Baize, Sylvain, Camara, Alseny-Modet, Maes, Piet, Shepherd, Susan, Danel, Christine, Carazo, Sara, Conde, Mamoudou N., Gala, Jean-Luc, Colin, Géraldine, Savini, Hélène, Bore, Joseph Akoi, Le Marcis, Frederic, Koundouno, Fara Raymond, Petitjean, Frédéric, Lamah, Marie-Claire, Diederich, Sandra, Tounkara, Alexis, Poelart, Geertrui, Berbain, Emmanuel, Dindart, Jean-Michel, Duraffour, Sophie, Lefevre, Annabelle, Leno, Tamba, Peyrouset, Olivier, Irenge, Léonid, Bangoura, N'Famara, Palich, Romain, Hinzmann, Julia, Kraus, Annette, Barry, Thierno Sadou, Berette, Sakoba, Bongono, André, Camara, Mohamed Seto, Chanfreau Munoz, Valérie, Doumbouya, Lanciné, Souley Harouna, Kighoma, Patient Mumbere, Koundouno, Fara Roger, Réné Lolamou, Loua, Cécé Moriba, Massala, Vincent, Moumouni, Kinda, Provost, Célia, Samake, Nenefing, Sekou, Conde, Soumah, Abdoulaye, Arnould, Isabelle, Komano, Michel Saa, Gustin, Lina, Berutto, Carlotta, Camara, Diarra, Camara, Fodé Saydou, Colpaert, Joliene, Delamou, Léontine, Jansson, Lena, Kourouma, Etienne, Loua, Maurice, Malme, Kristian, Manfrin, Emma, Maomou, André, Milinouno, Adele, Ombelet, Sien, Sidiboun, Aboubacar Youla, Verreckt, Isabelle, Yombouno, Pauline, Bocquin, Anne, Carbonnelle, Caroline, Carmoi, Thierry, Frange, Pierre, Mely, Stéphane, Nguyen, Vinh-Kim, Pannetier, Delphine, Taburet, Anne-Marie, Treluyer, Jean-Marc, Kolie, Jacques, Moh, Raoul, Gonzalez, Minerva Cervantes, Kuisma, Eeva, Liedigk, Britta, Ngabo, Didier, Rudolf, Martin, Thom, Ruth, Kerber, Romy, Gabriel, Martin, Di Caro, Antonino, Wölfel, Roman, Badir, Jamal, Bentahir, Mostafa, Deccache, Yann, Dumont, Catherine, Durant, Jean-François, El Bakkouri, Karim, Gasasira Uwamahoro, Marie, Smits, Benjamin, Toufik, Nora, Van Cauwenberghe, Stéphane, Ezzedine, Khaled, Dortenzio, Eric, Pizarro, Louis, Etienne, Aurélie, Guedj, Jérémie, Fizet, Alexandra, Barte de Sainte Fare, Eric, Murgue, Bernadette, Tran-Minh, Tuan, Rapp, Christophe, Piguet, Pascal, Poncin, Marc, Draguez, Bertrand, Allaford Duverger, Thierry, Barbe, Solenne, Baret, Guillaume, Defourny, Isabelle, Carroll, Miles, Raoul, Hervé, Augier, Augustin, Eholie, Serge P., Yazdanpanah, Yazdan, Levy-Marchal, Claire, Antierrens, Annick, Van Herp, Michel, Günther, Stephan, de Lamballerie, Xavier, Keïta, Sakoba, Mentre, France, Anglaret, Xavier, and Malvy, Denis

Subjects
Ebola hemorrhagic fever -- Drug therapy, Antiviral agents -- Patient outcomes, Biological sciences
Abstract

Background Ebola virus disease (EVD) is a highly lethal condition for which no specific treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the World Health Organization released a short list of drugs suitable for EVD research. Favipiravir, an antiviral developed for the treatment of severe influenza, was one of these. In late 2014, the conditions for starting a randomized Ebola trial were not fulfilled for two reasons. One was the perception that, given the high number of patients presenting simultaneously and the very high mortality rate of the disease, it was ethically unacceptable to allocate patients from within the same family or village to receive or not receive an experimental drug, using a randomization process impossible to understand by very sick patients. The other was that, in the context of rumors and distrust of Ebola treatment centers, using a randomized design at the outset might lead even more patients to refuse to seek care. Therefore, we chose to conduct a multicenter non-randomized trial, in which all patients would receive favipiravir along with standardized care. The objectives of the trial were to test the feasibility and acceptability of an emergency trial in the context of a large Ebola outbreak, and to collect data on the safety and effectiveness of favipiravir in reducing mortality and viral load in patients with EVD. The trial was not aimed at directly informing future guidelines on Ebola treatment but at quickly gathering standardized preliminary data to optimize the design of future studies. Methods and Findings Inclusion criteria were positive Ebola virus reverse transcription PCR (RT-PCR) test, age [greater than or equal to] 1 y, weight [greater than or equal to] 10 kg, ability to take oral drugs, and informed consent. All participants received oral favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d). Semi-quantitative Ebola virus RT-PCR (results expressed in 'cycle threshold' [Ct]) and biochemistry tests were performed at day 0, day 2, day 4, end of symptoms, day 14, and day 30. Frozen samples were shipped to a reference biosafety level 4 laboratory for RNA viral load measurement using a quantitative reference technique (genome copies/milliliter). Outcomes were mortality, viral load evolution, and adverse events. The analysis was stratified by age and Ct value. A 'target value' of mortality was defined a priori for each stratum, to guide the interpretation of interim and final analysis. Between 17 December 2014 and 8 April 2015, 126 patients were included, of whom 111 were analyzed (adults and adolescents, [greater than or equal to]13 y, n = 99; young children, [less than or equal to]6 y, n = 12). Here we present the results obtained in the 99 adults and adolescents. Of these, 55 had a baseline Ct value [greater than or equal to] 20 (Group A Ct [greater than or equal to] 20), and 44 had a baseline Ct value < 20 (Group A Ct < 20). Ct values and RNA viral loads were well correlated, with Ct = 20 corresponding to RNA viral load = 7.7 log.sub.10 genome copies/ml. Mortality was 20% (95% CI 11.6%-32.4%) in Group A Ct [greater than or equal to] 20 and 91% (95% CI 78.8%-91.1%) in Group A Ct < 20. Both mortality 95% CIs included the predefined target value (30% and 85%, respectively). Baseline serum creatinine was [greater than or equal to]110 [mu]mol/l in 48% of patients in Group A Ct [greater than or equal to] 20 ([greater than or equal to]300 [mu]mol/l in 14%) and in 90% of patients in Group A Ct < 20 ([greater than or equal to]300 [mu]mol/l in 44%). In Group A Ct [greater than or equal to] 20, 17% of patients with baseline creatinine [greater than or equal to]110 [mu]mol/l died, versus 97% in Group A Ct < 20. In patients who survived, the mean decrease in viral load was 0.33 log.sub.10 copies/ml per day of follow-up. RNA viral load values and mortality were not significantly different between adults starting favipiravir within Conclusions In the context of an outbreak at its peak, with crowded care centers, randomizing patients to receive either standard care or standard care plus an experimental drug was not felt to be appropriate. We did a non-randomized trial. This trial reaches nuanced conclusions. On the one hand, we do not conclude on the efficacy of the drug, and our conclusions on tolerance, although encouraging, are not as firm as they could have been if we had used randomization. On the other hand, we learned about how to quickly set up and run an Ebola trial, in close relationship with the community and non-governmental organizations; we integrated research into care so that it improved care; and we generated knowledge on EVD that is useful to further research. Our data illustrate the frequency of renal dysfunction and the powerful prognostic value of low Ct values. They suggest that drug trials in EVD should systematically stratify analyses by baseline Ct value, as a surrogate of viral load. They also suggest that favipiravir monotherapy merits further study in patients with medium to high viremia, but not in those with very high viremia. Trial registration ClinicalTrials.gov NCT02329054, Author(s): Daouda Sissoko 1,2, Cedric Laouenan 3,4, Elin Folkesson 5, Abdoul-Bing M'Lebing 6, Abdoul-Habib Beavogui 7, Sylvain Baize 8,9, Alseny-Modet Camara 5, Piet Maes 10,11, Susan Shepherd 6, Christine Danel [...]

Published
2016
Full Text
View/download PDF

17. Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study

Author

Kerber, Romy, primary, Lorenz, Eva, additional, Duraffour, Sophie, additional, Sissoko, Daouda, additional, Rudolf, Martin, additional, Jaeger, Anna, additional, Cisse, Sekou Ditinn, additional, Camara, Alseny-Modet, additional, Miranda, Osvaldo, additional, Castro, Carlos M, additional, Akoi Bore, Joseph, additional, Raymond Koundouno, Fara, additional, Repits, Johanna, additional, Afrough, Babak, additional, Becker-Ziaja, Beate, additional, Hinzmann, Julia, additional, Mertens, Marc, additional, Vitoriano, Ines, additional, Hugh Logue, Christopher, additional, Böttcher, Jan-Peter, additional, Pallasch, Elisa, additional, Sachse, Andreas, additional, Bah, Amadou, additional, Cabeza-Cabrerizo, Mar, additional, Nitzsche, Katja, additional, Kuisma, Eeva, additional, Michel, Janine, additional, Holm, Tobias, additional, Zekeng, Elsa Gayle, additional, Cowley, Lauren A, additional, Garcia-Dorival, Isabel, additional, Hetzelt, Nicole, additional, Baum, Jonathan Hans Josef, additional, Portmann, Jasmine, additional, Carter, Lisa, additional, Yenamaberhan, Rahel Lemma, additional, Camino, Alvaro, additional, Enkirch, Theresa, additional, Singethan, Katrin, additional, Meisel, Sarah, additional, Mazzarelli, Antonio, additional, Kosgei, Abigail, additional, Kafetzopoulou, Liana, additional, Rickett, Natasha Y, additional, Patrono, Livia Victoria, additional, Ghebreghiorghis, Luam, additional, Arnold, Ulrike, additional, Colin, Géraldine, additional, Juchet, Sylvain, additional, Marchal, Claire Levy, additional, Kolie, Jacques Seraphin, additional, Beavogui, Abdoul Habib, additional, Wurr, Stephanie, additional, Bockholt, Sabrina, additional, Krumkamp, Ralf, additional, May, Jürgen, additional, Stoecker, Kilian, additional, Fleischmann, Erna, additional, Ippolito, Giuseppe, additional, Carroll, Miles W, additional, Koivogui, Lamine, additional, Magassouba, N’Faly, additional, Keita, Sakoba, additional, Gurry, Céline, additional, Drury, Patrick, additional, Diallo, Boubacar, additional, Formenty, Pierre, additional, Wölfel, Roman, additional, Caro, Antonino Di, additional, Gabriel, Martin, additional, Anglaret, Xavier, additional, Malvy, Denis, additional, and Günther, Stephan, additional

Published
2019
Full Text
View/download PDF

18. Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent with Bacterial Translocation across the Gut

Author

Carroll, Miles W., primary, Haldenby, Sam, additional, Rickett, Natasha Y., additional, Pályi, Bernadett, additional, Garcia-Dorival, Isabel, additional, Liu, Xuan, additional, Barker, Gary, additional, Bore, Joseph Akoi, additional, Koundouno, Fara Raymond, additional, Williamson, E. Diane, additional, Laws, Thomas R., additional, Kerber, Romy, additional, Sissoko, Daouda, additional, Magyar, Nóra, additional, Di Caro, Antonino, additional, Biava, Mirella, additional, Fletcher, Tom E., additional, Sprecher, Armand, additional, Ng, Lisa F. P., additional, Rénia, Laurent, additional, Magassouba, N’faly, additional, Günther, Stephan, additional, Wölfel, Roman, additional, Stoecker, Kilian, additional, Matthews, David A., additional, and Hiscox, Julian A., additional

Published
2017
Full Text
View/download PDF

19. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus

Author

Liu, Xuan, primary, Speranza, Emily, additional, Muñoz-Fontela, César, additional, Haldenby, Sam, additional, Rickett, Natasha Y., additional, Garcia-Dorival, Isabel, additional, Fang, Yongxiang, additional, Hall, Yper, additional, Zekeng, Elsa-Gayle, additional, Lüdtke, Anja, additional, Xia, Dong, additional, Kerber, Romy, additional, Krumkamp, Ralf, additional, Duraffour, Sophie, additional, Sissoko, Daouda, additional, Kenny, John, additional, Rockliffe, Nichola, additional, Williamson, E. Diane, additional, Laws, Thomas R., additional, N’Faly, Magassouba, additional, Matthews, David A., additional, Günther, Stephan, additional, Cossins, Andrew R., additional, Sprecher, Armand, additional, Connor, John H., additional, Carroll, Miles W., additional, and Hiscox, Julian A., additional

Published
2017
Full Text
View/download PDF

20. Ebola Virus Disease Is Characterized by Poor Activation and Reduced Levels of Circulating CD16 + Monocytes

Author

Lüdtke, Anja, primary, Ruibal, Paula, additional, Becker-Ziaja, Beate, additional, Rottstegge, Monika, additional, Wozniak, David M., additional, Cabeza-Cabrerizo, Mar, additional, Thorenz, Anja, additional, Weller, Romy, additional, Kerber, Romy, additional, Idoyaga, Juliana, additional, Magassouba, N'Faly, additional, Gabriel, Martin, additional, Günther, Stephan, additional, Oestereich, Lisa, additional, and Muñoz-Fontela, César, additional

Published
2016
Full Text
View/download PDF

21. Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever

Author

Oestereich, Lisa, primary, Lüdtke, Anja, additional, Ruibal, Paula, additional, Pallasch, Elisa, additional, Kerber, Romy, additional, Rieger, Toni, additional, Wurr, Stephanie, additional, Bockholt, Sabrina, additional, Pérez-Girón, José V., additional, Krasemann, Susanne, additional, Günther, Stephan, additional, and Muñoz-Fontela, César, additional

Published
2016
Full Text
View/download PDF

22. Aufbau von Replikonsystemen für Altwelt-Arenaviren und Herstellung rekombinanter Mopeia-Viren

Author

Kerber, Romy, Dotzauer, Andreas, and Günther, Stephan

Subjects
lymphocytic choriomeningitis virus, viruses, ddc:570, virus diseases, 570 Life sciences, biology, Mopeia virus, Old World arenaviruses, Lassa virus, reverse genetic systems
Abstract

Lassa virus (LASV) causing hemorrhagic fever, Mopeia virus (MOPV) and lymphocytic choriomeningitis virus (LCMV) are the main representatives of the Old World arenaviruses. Minireplicon systems for MOPV and LCMV were established in analogy to the existing LASV system. The functional and physical integrity of replication complexes was tested by luciferase assay, Northern blotting, and coimmunoprecipitation studies. The minigenomes, NPs, and L proteins of LASV and MOPV could be exchanged without loss of function LASV and MOPV L proteins are functional also with LCMV NP, while the LCMV L protein requires homologous NP for activity. Analysis of LASV/LCMV NP chimeras identified a single LCMV-specific NP residue (Ile-53) and the C terminus of NP as being essential for LCMV L protein function. The defect of LASV and MOPV NP in supporting transcriptional activity of LCMV L protein was not caused by a defect in physical NP-L protein interaction. Furthermore the first reverse genetic system for production of infectious MOPV was established. Overall, new reverse genetic systems were established to study the replication cycle of Old World arenaviruses.

Published
2011

24. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus.

Author

Xuan Liu, Speranza, Emily, Muñoz-Fontela, César, Haldenby, Sam, Rickett, Natasha Y., Garcia-Dorival, Isabel, Yongxiang Fang, Hall, Yper, Zekeng, Elsa-Gayle, Lüdtke, Anja, Dong Xia, Kerber, Romy, Krumkamp, Ralf, Duraffour, Sophie, Sissoko, Daouda, Kenny, John, Rockliffe, Nichola, Williamson, E. Diane, Laws, Thomas R., and N'Faly, Magassouba

Published
2017
Full Text
View/download PDF

25. Ebola Virus Disease Is Characterized by Poor Activation and Reduced Levels of Circulating CD16+ Monocytes.

Author

Lüdtke, Anja, Ruibal, Paula, Becker-Ziaja, Beate, Rottstegge, Monika, Wozniak, David M., Cabeza-Cabrerizo, Mar, Thorenz, Anja, Weller, Romy, Kerber, Romy, Idoyaga, Juliana, Magassouba, N'Faly, Gabriel, Martin, Günther, Stephan, Oestereich, Lisa, and Muñoz-Fontela, César

Subjects
EBOLA virus disease, CD antigens, VIRUS inactivation, MONOCYTES, DENDRITIC cells, NEUTROPHILS, DIAGNOSIS
Abstract

A number of previous studies have identified antigen-presenting cells (APCs) as key targets of Ebola virus (EBOV), but the role of APCs in human Ebola virus disease (EVD) is not known. We have evaluated the phenotype and kinetics of monocytes, neutrophils, and dendritic cells (DCs) in peripheral blood of patients for whom EVD was diagnosed by the European Mobile Laboratory in Guinea. Acute EVD was characterized by reduced levels of circulating nonclassical CD16+ monocytes with a poor activation profile. In survivors, CD16+ monocytes were activated during recovery, coincident with viral clearance, suggesting an important role of this cell subset in EVD pathophysiology. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

27. Structure of the Lassa Virus Nucleoprotein Revealed by X-ray Crystallography, Small-angle X-ray Scattering, and Electron Microscopy

Author

Brunotte, Linda, primary, Kerber, Romy, additional, Shang, Weifeng, additional, Hauer, Florian, additional, Hass, Meike, additional, Gabriel, Martin, additional, Lelke, Michaela, additional, Busch, Carola, additional, Stark, Holger, additional, Svergun, Dmitri I., additional, Betzel, Christian, additional, Perbandt, Markus, additional, and Günther, Stephan, additional

Published
2011
Full Text
View/download PDF

28. The N-Terminal Domain of the Arenavirus L Protein Is an RNA Endonuclease Essential in mRNA Transcription

Author

Morin, Benjamin, primary, Coutard, Bruno, additional, Lelke, Michaela, additional, Ferron, François, additional, Kerber, Romy, additional, Jamal, Saïd, additional, Frangeul, Antoine, additional, Baronti, Cécile, additional, Charrel, Rémi, additional, de Lamballerie, Xavier, additional, Vonrhein, Clemens, additional, Lescar, Julien, additional, Bricogne, Gérard, additional, Günther, Stephan, additional, and Canard, Bruno, additional

Published
2010
Full Text
View/download PDF

29. Cross-species analysis of the replication complex of Old World arenaviruses reveals two sites in nucleoprotein involved in L protein function

Author

Kerber Romy, Rieger Toni, Busch Carola, Flatz Lukas, Pinschewer Daniel D, Kümmerer Beate M, and Günther Stephan

Subjects
viruses, virus diseases
Abstract

Lassa virus (LASV) causing hemorrhagic Lassa fever in West Africa Mopeia Virus (MOPV) from East Africa and lymphocytic choriomeningitis virus (LCMV) are main representatives of the Old World arenaviruses. Little is known on how the components of the arenavirus replication machinery genome nucleoprotein (NP) and L protein interact. In addition it is unknown if these components can function across species boundaries. We established minireplicon systems for MOPV and LCMV in analogy to the existing LASV system and exchanged the components among the three systems. Functional and physical integrity of the resulting complexes was tested by reporter gene assay Northern blot and co immunoprecipitation studies. Minigenome NP and L protein of LASV and MOPV could be exchanged without loss of function. LASV and MOPV L protein was also active in conjunction with LCMV NP while the LCMV L protein required homologous NP for activity. Analysis of LASV/LCMV NP chimeras identified a single LCMV specific NP residue (Ile 53) and the C terminus of NP (residues 340 558) as being essential for LCMV L protein function. The defect of LASV and MOPV NP in supporting transcriptional activity of LCMV L protein was not caused by a defect in physical NP L protein interaction. In conclusion components of the replication complex of Old World arenaviruses have the potential to functionally and physically interact across species boundaries. Residue 53 and the C terminal domain of NP are important for function of L protein during genome replication and transcription.

Full Text
View/download PDF

30. Aufbau von Replikonsystemen für Altwelt-Arenaviren und Herstellung rekombinanter Mopeia-Viren

Author

Kerber, Romy and Kerber, Romy

Abstract

Lassa virus (LASV) causing hemorrhagic fever, Mopeia virus (MOPV) and lymphocytic choriomeningitis virus (LCMV) are the main representatives of the Old World arenaviruses. Minireplicon systems for MOPV and LCMV were established in analogy to the existing LASV system. The functional and physical integrity of replication complexes was tested by luciferase assay, Northern blotting, and coimmunoprecipitation studies. The minigenomes, NPs, and L proteins of LASV and MOPV could be exchanged without loss of function LASV and MOPV L proteins are functional also with LCMV NP, while the LCMV L protein requires homologous NP for activity. Analysis of LASV/LCMV NP chimeras identified a single LCMV-specific NP residue (Ile-53) and the C terminus of NP as being essential for LCMV L protein function. The defect of LASV and MOPV NP in supporting transcriptional activity of LCMV L protein was not caused by a defect in physical NP-L protein interaction. Furthermore the first reverse genetic system for production of infectious MOPV was established. Overall, new reverse genetic systems were established to study the replication cycle of Old World arenaviruses.

31. Aufbau von Replikonsystemen für Altwelt-Arenaviren und Herstellung rekombinanter Mopeia-Viren

Author

Kerber, Romy and Kerber, Romy

Abstract

Lassa virus (LASV) causing hemorrhagic fever, Mopeia virus (MOPV) and lymphocytic choriomeningitis virus (LCMV) are the main representatives of the Old World arenaviruses. Minireplicon systems for MOPV and LCMV were established in analogy to the existing LASV system. The functional and physical integrity of replication complexes was tested by luciferase assay, Northern blotting, and coimmunoprecipitation studies. The minigenomes, NPs, and L proteins of LASV and MOPV could be exchanged without loss of function LASV and MOPV L proteins are functional also with LCMV NP, while the LCMV L protein requires homologous NP for activity. Analysis of LASV/LCMV NP chimeras identified a single LCMV-specific NP residue (Ile-53) and the C terminus of NP as being essential for LCMV L protein function. The defect of LASV and MOPV NP in supporting transcriptional activity of LCMV L protein was not caused by a defect in physical NP-L protein interaction. Furthermore the first reverse genetic system for production of infectious MOPV was established. Overall, new reverse genetic systems were established to study the replication cycle of Old World arenaviruses.

32. Aufbau von Replikonsystemen für Altwelt-Arenaviren und Herstellung rekombinanter Mopeia-Viren

Author

Kerber, Romy and Kerber, Romy

Abstract

Lassa virus (LASV) causing hemorrhagic fever, Mopeia virus (MOPV) and lymphocytic choriomeningitis virus (LCMV) are the main representatives of the Old World arenaviruses. Minireplicon systems for MOPV and LCMV were established in analogy to the existing LASV system. The functional and physical integrity of replication complexes was tested by luciferase assay, Northern blotting, and coimmunoprecipitation studies. The minigenomes, NPs, and L proteins of LASV and MOPV could be exchanged without loss of function LASV and MOPV L proteins are functional also with LCMV NP, while the LCMV L protein requires homologous NP for activity. Analysis of LASV/LCMV NP chimeras identified a single LCMV-specific NP residue (Ile-53) and the C terminus of NP as being essential for LCMV L protein function. The defect of LASV and MOPV NP in supporting transcriptional activity of LCMV L protein was not caused by a defect in physical NP-L protein interaction. Furthermore the first reverse genetic system for production of infectious MOPV was established. Overall, new reverse genetic systems were established to study the replication cycle of Old World arenaviruses.

33. A Basic Cluster in the N Terminus of Yellow Fever Virus NS2A Contributes to Infectious Particle Production.

Author

Voβmann, Stephanie, Wieseler, Janett, Kerber, Romy, and Kümmerer, Beate Mareike

Subjects
*FLAVIVIRUSES, *ANTISENSE DNA, *SUPPRESSOR mutation, *VIRUSES, *GENETIC mutation
Abstract

The flavivirus NS2A protein is involved in the assembly of infectious particles. To further understand its role in this process, a charged-to-alanine scanning analysis was performed on NS2A encoded by an infectious cDNA clone of yellow fever virus (YFV). Fifteen mutants containing single, double, or triple charged-to-alanine changes were tested. Five of them did not produce infectious particles, whereas efficient RNA replication was detectable for two of the five NS2A mutants (R22A-K23A-R24A and R99AE100A- R101A mutants). Prolonged cultivation of transfected cells resulted in the recovery of pseudorevertants. Besides suppressor mutants in NS2A, a compensating second-site mutation in NS3 (D343G) arose for the NS2A R22A-K23A-R24A mutant. We found this NS3 mutation previously to be suppressive for the NS2A cleavage site Q189S mutant, also deficient in virion assembly. In this study, the subsequently suggested interaction between NS2A and NS3 was proven by coimmunoprecipitation analyses. Using selectively permeabilized cells, we could demonstrate that the regions encompassing R22A-K23A-R24A and Q189S in NS2A are localized to the cytoplasm, where NS3 is also known to reside. However, the defect in particle production observed for the NS2A R22A-K23A-R24A and Q189S mutants was not due to a defect in physical interaction between NS2A and NS3, as the NS2A mutations did not interrupt NS3 interaction. In fact, a region just upstream of R22-K23-R24 was mapped to be critical for NS2A-NS3 interaction. Taken together, these data support a complex interplay between YFV NS2A and NS3 in virion assembly and identify a basic cluster in the NS2A N terminus to be critical in this process. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

34. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Author

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, and Malvy D

Abstract

[This corrects the article DOI: 10.1371/journal.pmed.1001967.].

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results